Acquired by Pfizer in Oct 2022
GBT - Global Blood Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
South San Francisco,
United States
Type: Equity
GBT price evolution
GBT
| (in millions $) | 30 Jun 2022 | 31 Mar 2022 | 31 Dec 2021 | 30 Sep 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $263.58 | $394.25 | $687.15 | $385.32 |
| Short term investments | $256.01 | $161.61 | $3.21 | |
| Net receivables | $29.77 | $27.73 | $28.8 | $23.89 |
| Inventory | $65.82 | $61.96 | $58.2 | $51.51 |
| Total current assets | $640.01 | $675.65 | $801.97 | $488.86 |
| Long term investments | $146.86 | $108.67 | $50.06 | $30.69 |
| Property, plant & equipment | $78.92 | $80.87 | $82.93 | $84.15 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $230.43 | $193.9 | $137.24 | $118.81 |
| Total investments | $402.87 | $270.28 | $50.06 | $33.9 |
| Total assets | $870.44 | $869.54 | $939.21 | $607.68 |
| Current liabilities | ||||
| Accounts payable | $8.26 | $5.42 | $15.1 | $8.64 |
| Deferred revenue | ||||
| Short long term debt | $5.45 | |||
| Total current liabilities | $93.09 | $79.31 | $88 | $74.06 |
| Long term debt | $652.27 | $653.16 | $653.95 | $224.5 |
| Total noncurrent liabilities | $658.99 | $656.24 | $654.8 | $225.32 |
| Total debt | $652.27 | $653.16 | $653.95 | $229.95 |
| Total liabilities | $752.08 | $735.54 | $742.8 | $299.38 |
| Shareholders' equity | ||||
| Retained earnings | -$1453.45 | -$1370.98 | -$1289.56 | -$1201.98 |
| Other shareholder equity | -$3.97 | -$1.96 | $0.1 | $0.22 |
| Total shareholder equity | $118.36 | $134 | $196.41 | $308.3 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $687.15 | $497.2 | $304.63 | $277.75 |
| Short term investments | $66.13 | $307.73 | $202.18 | |
| Net receivables | $28.8 | $17.5 | $2.64 | |
| Inventory | $58.2 | $40.22 | $1.28 | |
| Total current assets | $801.97 | $632.16 | $628 | $485.78 |
| Long term investments | $50.06 | $85.03 | $114.28 | |
| Property, plant & equipment | $82.93 | $88.6 | $79.89 | $14.98 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $137.24 | $91.84 | $168.1 | $131.86 |
| Total investments | $50.06 | $66.13 | $392.76 | $316.46 |
| Total assets | $939.21 | $724 | $796.1 | $617.64 |
| Current liabilities | ||||
| Accounts payable | $15.1 | $19.08 | $10.62 | $6.05 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $88 | $79.03 | $71.45 | $33.77 |
| Long term debt | $653.95 | $227.99 | $145.92 | |
| Total noncurrent liabilities | $654.8 | $228.81 | $145.95 | $11.07 |
| Total debt | $653.95 | $227.99 | $145.92 | |
| Total liabilities | $742.8 | $307.85 | $217.41 | $44.84 |
| Shareholders' equity | ||||
| Retained earnings | -$1289.56 | -$986.47 | -$738.92 | -$472.15 |
| Other shareholder equity | $0.1 | $0.3 | $0.75 | -$0.05 |
| Total shareholder equity | $196.41 | $416.16 | $578.69 | $572.8 |
| (in millions $) | 30 Jun 2022 | 31 Mar 2022 | 31 Dec 2021 | 30 Sep 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $71.55 | $55.16 | $56.1 | $52.05 |
| Cost of revenue | $1.41 | $1.05 | $1.15 | $0.83 |
| Gross Profit | $70.14 | $54.1 | $54.95 | $51.22 |
| Operating activities | ||||
| Research & development | $64.78 | $52.83 | $58.97 | $50.53 |
| Selling, general & administrative | $81.09 | $74.53 | $78.94 | $67.99 |
| Total operating expenses | $145.86 | $127.37 | $137.91 | $118.52 |
| Operating income | -$75.73 | -$73.26 | -$82.96 | -$67.29 |
| Income from continuing operations | ||||
| EBIT | -$73.88 | -$73.05 | -$82.71 | -$67.28 |
| Income tax expense | $0.19 | $0.17 | $0.48 | |
| Interest expense | $8.4 | $8.21 | $4.39 | $3.71 |
| Net income | ||||
| Net income | -$82.47 | -$81.42 | -$87.58 | -$70.99 |
| Income (for common shares) | -$82.47 | -$81.42 | -$87.58 | -$70.99 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $194.75 | $123.8 | $2.11 | |
| Cost of revenue | $3.32 | $1.99 | $0.05 | |
| Gross Profit | $191.43 | $121.82 | $2.06 | |
| Operating activities | ||||
| Research & development | $212.13 | $155.12 | $174.56 | $131.31 |
| Selling, general & administrative | $266.99 | $210.85 | $117.09 | $51.44 |
| Total operating expenses | $479.12 | $365.97 | $291.64 | $182.74 |
| Operating income | -$287.69 | -$244.16 | -$289.58 | -$182.74 |
| Income from continuing operations | ||||
| EBIT | -$287.15 | -$237.74 | -$266.77 | -$174.19 |
| Income tax expense | $0.48 | |||
| Interest expense | $15.47 | $9.81 | ||
| Net income | ||||
| Net income | -$303.09 | -$247.55 | -$266.77 | -$174.19 |
| Income (for common shares) | -$303.09 | -$247.55 | -$266.77 | -$174.19 |
| (in millions $) | 30 Jun 2022 | 31 Mar 2022 | 31 Dec 2021 | 30 Sep 2021 |
|---|---|---|---|---|
| Net income | -$82.47 | -$81.42 | -$87.58 | -$70.99 |
| Operating activities | ||||
| Depreciation | $2.31 | $2.27 | $2.22 | $2.19 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $19.84 | $19.14 | $19.41 | $18.08 |
| Total cash flows from operations | -$44.31 | -$71.85 | -$67.93 | -$65.31 |
| Investing activities | ||||
| Capital expenditures | -$0.38 | -$0.25 | -$1.05 | -$0.26 |
| Investments | -$134.28 | -$222.25 | -$16.46 | -$15.87 |
| Total cash flows from investing | -$134.66 | -$222.5 | -$17.51 | -$16.13 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $48.71 | $2.58 | $2.88 | $46.18 |
| Net borrowings | $431.17 | |||
| Total cash flows from financing | $48.6 | $1.6 | $387.17 | $45.09 |
| Effect of exchange rate | -$0.3 | -$0.15 | $0.1 | -$0.04 |
| Change in cash and equivalents | -$130.67 | -$292.9 | $301.83 | -$36.39 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Net income | -$303.09 | -$247.55 | -$266.77 | -$174.19 |
| Operating activities | ||||
| Depreciation | $8.62 | $10.82 | $9.93 | $4.61 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $78.67 | $71.48 | $45.65 | $30.08 |
| Total cash flows from operations | -$256.81 | -$211.86 | -$194.42 | -$135.38 |
| Investing activities | ||||
| Capital expenditures | -$3.23 | -$8.75 | -$3.42 | -$4.75 |
| Investments | $15.34 | $326.07 | -$73.45 | -$179.41 |
| Total cash flows from investing | $12.11 | $317.31 | -$76.86 | -$184.16 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $53.14 | $17.61 | $233.3 | $404.16 |
| Net borrowings | $431.12 | $74.8 | $72.47 | |
| Total cash flows from financing | $434.33 | $87.12 | $298.16 | $397.91 |
| Effect of exchange rate | $0.32 | |||
| Change in cash and equivalents | $189.95 | $192.57 | $26.88 | $78.37 |
News
|
3 Beaten-Down Stocks to Buy and Hold
Motley Fool
15 Oct 2022
|
|
Why Shares of Keros Therapeutics Rose 10.2% This Week
Motley Fool
14 Oct 2022
|
|
Did The Texas ESG Ban Have Any Bite?
Forbes
14 Oct 2022
|
|
Kyverna Therapeutics Names Peter Maag, Ph.D., as Chief Executive Officer
FOX 19 Cincinnati
13 Oct 2022
|
|
Pfizer: An Excellent Combinati - GuruFocus.com
Guru Focus
10 Oct 2022
|
|
Gastrointestinal Stromal Tumors Therapeutics Market Size to Grow by USD 1.08 Bn, Growing Geriatric...
The Longview News-Journal
9 Oct 2022
|
|
5 Stocks to Delete From Your Watchlist in Q4
Entrpreneur
7 Oct 2022
|
|
Should First Trust Small Cap Growth AlphaDEX ETF (FYC) Be on Your Investing Radar?
Zacks via Yahoo Finance
6 Oct 2022
|
|
Lennox-Gastaut Syndrome Treatment Market 2026, Rising Population With Risk Factors For LGS to Boost...
The Longview News-Journal
5 Oct 2022
|
|
Will Acquisitions Help Novo Nordisk (NVO) Combat Stiff Rivalry?
Zacks via Yahoo Finance
3 Oct 2022
|
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 67.27M |
| Revenue | $234.86M |
|---|---|
| EBITDA | -$287.94M |
| EBIT | -$296.91M |
| Net Income | -$322.46M |
| Revenue Q/Q | 50.46% |
| Revenue Y/Y | 42.53% |
| P/E ratio | 0.00 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 0.00 |
| Book/Share | 1.82 |
| Cash/Share | 3.92 |
| EPS | -$4.79 |
|---|---|
| ROA | -39.24% |
| ROE | -170.37% |
| Debt/Equity | 3.78 |
|---|---|
| Net debt/EBITDA | -1.70 |
| Current ratio | 6.88 |
| Quick ratio | 6.17 |